What is HC Wainwright's Estimate for Annexon Q3 Earnings?

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Annexon to a loss of $0.27 per share from a prior loss estimate of $0.22, while maintaining a Buy rating and $14 price target.
• The firm projects continued losses through 2028, followed by modest profitability of $0.03 per share in 2029 and $0.45 in 2030. Annexon’s latest quarterly loss of $0.28 per share also missed the consensus estimate of $0.24.
• Analyst views remain mixed: five rate the stock Buy, three Hold and two Sell, resulting in a consensus Hold rating and average price target of $15.33 versus the stock’s recent price near $5.29.

Annexon, Inc. (NASDAQ:ANNX - Free Report) - Stock analysts at HC Wainwright cut their Q3 2026 earnings estimates for Annexon in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.27) per share for the quarter, down from their prior estimate of ($0.22). HC Wainwright has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Annexon's current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Annexon's FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at $0.03 EPS and FY2030 earnings at $0.45 EPS.

Several other equities analysts also recently weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a research note on Monday, July 13th. Citigroup began coverage on Annexon in a research report on Tuesday, July 21st. They set a "market underperform" rating on the stock. Needham & Company LLC upped their target price on Annexon from $11.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Annexon in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded Annexon from a "sell" rating to a "strong sell" rating in a research note on Saturday. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $15.33.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $5.29 on Monday. The business's 50 day simple moving average is $5.35 and its 200-day simple moving average is $5.50. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -4.56 and a beta of 1.18. Annexon has a 12 month low of $2.03 and a 12 month high of $7.18.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04).

Insider Transactions at Annexon

In other Annexon news, Director Muneer A. Satter purchased 613,497 shares of the firm's stock in a transaction on Thursday, May 28th. The shares were purchased at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the purchase, the director owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 10.31% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of Annexon in the third quarter worth approximately $31,000. Engineers Gate Manager LP purchased a new stake in Annexon in the second quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. increased its position in Annexon by 65.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company's stock worth $35,000 after purchasing an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in Annexon during the fourth quarter worth approximately $50,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Annexon during the fourth quarter worth approximately $52,000.

Annexon News Summary

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $14 price target, substantially above the stock’s recent trading level near $5.29. The firm continues to project a path to profitability, with estimated positive EPS of $0.03 in 2029 and $0.45 in 2030. HC Wainwright earnings estimates and rating
• Neutral Sentiment: Citizens JMP upgraded Annexon to Market Perform, while WallStreetZen separately lowered its rating. The conflicting actions point to more cautious or mixed views among analysts rather than a clear change in the company’s fundamental outlook. Citizens JMP rating update WallStreetZen rating update
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026-2030, including Q3 2026 EPS to a $0.27 loss from a $0.22 loss, FY2026 to a $0.99 loss from $0.90, and FY2029 earnings to $0.03 from $0.13. The firm also cut its FY2030 estimate to $0.45 from $0.56. These revisions suggest higher expected losses or slower financial improvement. Annexon recently reported a quarterly loss of $0.28 per share, worse than the $0.24 consensus estimate. HC Wainwright revised estimates

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source